Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 3/20 | 0.66 |
| ▸ | DAO | P14920 | 1/20 | 0.56 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.55 |
| ▸ | KMO | O15229 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.53 |
| ▸ | ANPEP | P15144 | 1/20 | 0.53 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.53 |
| ▸ | MRGPRX4 | Q96LA9 | 3/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30395109 | 1.00 | FOLH1 (0.66) | FOLH1DAONR4A2KMT2AAKR1C3 | |
| SCHEMBL371526 | 0.96 | FOLH1 (0.70) | FOLH1NR4A2KMT2ACYP2D6CYP2C9 | |
| SCHEMBL1296456 | 0.92 | FOLH1 (0.61) | FOLH1KMT2AAKR1C3CYP2D6CYP2C9 | |
| SCHEMBL1980273 | 0.92 | FOLH1 (0.61) | FOLH1NR4A2KMT2AAKR1C3KMO | |
| Hydrochloric Acid SCHEMBL7138106 | 0.90 | FOLH1 (0.59) | FOLH1KMT2AAKR1C3CYP2D6CYP2C9 | |
| SCHEMBL27705270 | 0.89 | FOLH1 (0.58) | FOLH1DAOKMT2AAKR1C3CYP2D6 | |
| SCHEMBL1541757 | 0.88 | FOLH1 (0.61) | FOLH1NR4A2KMT2AAKR1C3CYP2D6 | |
| SCHEMBL16559877 | 0.88 | FOLH1 (0.66) | FOLH1NR4A2KMT2ACYP2D6CYP2C9 | |
| SCHEMBL27705284 | 0.87 | FOLH1 (0.56) | FOLH1DAONR4A2KMT2AAKR1C3 | |
| Benzoic Acid SCHEMBL4779307 | 0.87 | DAO (0.70) | FOLH1DAONR4A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107428923-B | Modifier for resin and resin composition using same | 株式会社ADEKA | 2020-03-03 | — | — | CN | disclosed |
| US-10424745-B2 | Organometallic complex, light-emitting element, display device, electronic device, and lighting device | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2019-09-24 | — | — | US | disclosed |
| US-20180212164-A1 | Organometallic Complex, Light-Emitting Element, Display Device, Electronic Device, and Lighting Device | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2018-07-26 | — | — | US | disclosed |
| EP-2743256-B1 | CYCLOPROPANEAMINE COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2018-06-27 | — | — | EP | disclosed |
| EP-2496591-B1 | ORGANOMETALLIC COMPLEX, LIGHT-EMITTING ELEMENT, DISPLAY DEVICE, ELECTRONIC DEVICE, AND LIGHTING DEVICE | SEMICONDUCTOR ENERGY LAB (JP) | 2018-05-30 | — | — | EP | disclosed |
| EP-1763509-B1 | ALPHA-HELICAL MIMETICS | WALTER & ELIZA HALL INST MEDICAL RES (AU) | 2018-02-21 | — | — | EP | disclosed |
| EP-2150526-B1 | N-ADAMANTYL BENZAMIDES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE | VTV THERAPEUTICS LLC (US) | 2017-09-20 | — | — | EP | disclosed |
| US-9682925-B2 | Cyclopropaneamine compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-06-20 | — | — | US | disclosed |
| CN-103842332-B | Cyclopropylamine compound | 武田药品工业株式会社 | 2016-08-17 | — | — | CN | disclosed |
| US-20160130215-A1 | CYCLOPROPANEAMINE COMPOUND | TAKEDA PHARMACEUTICAL (JP) | 2016-05-12 | — | — | US | disclosed |
| EP-1763509-A1 | ALPHA-HELICAL MIMETICS | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2007-03-21 | — | — | EP | disclosed |
| EP-1748046-A2 | Inhibitors of histone deacetylase | Methylgene, Inc. (CA) | 2007-01-31 | — | — | EP | disclosed |
| EP-1748046-A2 | Inhibitors of histone deacetylase | Methylgene, Inc. (CA) | 2007-01-31 | — | — | EP | disclosed |
| CN-1863768-A | Prostaglandin analogs as agonists of the EP4 receptor | HOFFMANN LA ROCHE (CH) | 2006-11-15 | — | — | CN | disclosed |
| WO-2006002474-A1 | ALPHA-HELICAL MIMETICS | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2006-01-12 | — | — | WO | disclosed |
| US-20050113450-A1 | Antibacterial agents | PHARMACIA & UPJOHN COMPANY | 2005-05-26 | — | — | US | disclosed |
| WO-2004018414-A2 | ANTIBACTERIAL AGENTS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-03-04 | — | — | WO | disclosed |
| US-6541661-B1 | For treating cell proliferative diseases and conditions | METHYLGENE, INC. (CA) | 2003-04-01 | — | — | US | disclosed |
| EP-1233958-A1 | INHIBITORS OF HISTONE DEACETYLASE | Methylgene, Inc. (CA) | 2002-08-28 | — | — | EP | disclosed |
| WO-2001038322-A1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE, INC. (CA) | 2001-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113450-A1 | Antibacterial agents | CLPP, SPOUT1, SAMHD1 | FOLH1 1837/4885DAO 463/4885NR4A2 4642/4885 |
| US-20160130215-A1 | CYCLOPROPANEAMINE COMPOUND | KDM1A, KDM1B, KDM3A | FOLH1 838/4885DAO 579/4885NR4A2 2647/4885 |
| US-10424745-B2 | Organometallic complex, light-emitting element, display device, electronic device, and lighting device | GRK1, CDKL1, ARL1 | FOLH1 4437/4885DAO 1750/4885NR4A2 319/4885 |
| US-20180212164-A1 | Organometallic Complex, Light-Emitting Element, Display Device, Electronic Device, and Lighting Device | GRK1, CDKL1, ARL1 | FOLH1 4437/4885DAO 1750/4885NR4A2 319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.